(Q30574153)

25 June 2017

1 reference

Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data (English)

1 reference

25 June 2017

1 reference

1

Ioannidis JP

1 reference

25 June 2017

Contopoulos-Ioannidis DG

series ordinal

2

1 reference

PubMed ID

10235168

25 June 2017

Lau J

series ordinal

3

1 reference

25 June 2017

1 April 1999

1 reference

Journal of Clinical Epidemiology

25 June 2017

1 reference

25 June 2017

52

1 reference

25 June 2017

281-291

1 reference

25 June 2017

4

1 reference

The existence of publication bias and risk factors for its occurrence

25 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Meta-analysis of the literature or of individual patient data: is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Cumulative meta-analysis of therapeutic trials for myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Uncertainty of the time of first significance in random effects cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Quantitative synthesis in systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

A pilot study of low-dose zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Meta-analysis. Unresolved issues and future developments

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Effective and acceptable treatment for depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

The impact of stopping rules on heterogeneity of results in overviews of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Stopping rules and estimation problems in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Practical problems in interim analyses, with particular regard to estimation

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Summing up evidence: one answer is not always enough.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Predictive ability of meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Large trials vs meta-analysis of smaller trials: how do their results compare?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Issues in comparisons between meta-analyses and large trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Meta-analyses of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Meta-analysis: is moving the goal post the answer?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

The population risk as an explanatory variable in research synthesis of clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from patient populations in trials of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

The impact of high-risk patients on the results of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2898%2900159-0

7 January 2021

10.1016/S0895-4356(98)00159-0

Identifiers

DOI

1 reference

release_x7yykiwcubaddjgul6cp2ay2oi

25 June 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x7yykiwcubaddjgul6cp2ay2oi

24 November 2022

mapped directly with Wikidata item

PubMed ID

10235168

1 reference

PubMed ID

10235168